DMAC · Insider Trading
DiaMedica Therapeutics Inc. Common Stock
Every open-market purchase and sale reported by DMAC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Dietrich John Pauls | President & CEO | A | +60,200 | — |
| 2026-06-03 | Julie Krop | Chief Medical Officer | A | +67,500 deriv. | — |
| 2026-06-03 | Daniel J. O'Connor | Director | A | +40,412 deriv. | — |
| 2026-06-03 | James T. Parsons | Director | A | +51,189 deriv. | — |
| 2026-06-03 | Dietrich John Pauls | President & CEO | A | +380,000 deriv. | — |
| 2026-06-03 | Scott Kellen | CFO & Secretary | A | +162,000 deriv. | — |
| 2026-06-03 | Tanya Lewis | Director | A | +40,412 deriv. | — |
| 2026-06-03 | Randall Michael Giuffre | Director | A | +40,412 deriv. | — |
| 2026-06-03 | Charles Pauling Semba | Director | A | +40,412 deriv. | — |
| 2026-06-03 | Richard Kuntz | Director | A | +40,412 deriv. | — |
| 2026-01-06 | Charles Pauling Semba | Director | A | +3,355 | +$28.25K |
| 2026-01-06 | James T. Parsons | Director | A | +10,095 | +$85.00K |
| 2026-01-06 | Randall Michael Giuffre | Director | A | +6,175 | +$51.99K |
| 2025-12-08 | Ab Trill | 10%+ Owner | Buy | +2,122,554 | +$15.26M |
| 2025-11-25 | James T. Parsons | Director | M | +12,000 | +$26.40K |
| 2025-11-03 | Julie Krop | Chief Marketing Officer | A | +450,000 deriv. | — |
| 2025-09-04 | Ab Trill | 10%+ Owner | Buy | +2,000,000 | +$11.92M |
| 2025-07-25 | Richard Jacinto II | 10%+ Owner | Buy | +400,000 | +$1.40M |
| 2025-07-25 | Ab Trill | 10%+ Owner | Buy | +3,085,714 | +$10.80M |
| 2025-07-25 | Thomas Von Koch | 10%+ Owner | Buy | +8,571,426 | +$30.00M |
| 2025-06-03 | Charles Pauling Semba | Director | A | — | — |
| 2025-06-03 | James T. Parsons | Director | A | — | — |
| 2025-06-03 | Tanya Lewis | Director | A | — | — |
| 2025-06-03 | Scott Kellen | CFO & Secretary | A | — | — |
| 2025-06-03 | Richard Kuntz | Director | A | — | — |
| 2025-06-03 | Randall Michael Giuffre | Director | A | — | — |
| 2025-06-03 | Dietrich John Pauls | President & CEO | A | — | — |
| 2025-06-03 | David J. Wambeke | Chief Business Officer | A | — | — |
| 2025-04-08 | Richard D. Pilnik | Director | M | +24,000 | +$50.64K |
| 2025-02-24 | Daniel J. O'Connor | Director | A | — | — |
| 2025-02-18 | Randall Michael Giuffre | Director | M | +17,000 | +$43.57K |
| 2025-01-03 | James T. Parsons | Director | A | +15,917 | +$85.00K |
| 2025-01-03 | Richard D. Pilnik | Director | A | +10,393 | +$55.50K |
| 2025-01-03 | Charles Pauling Semba | Director | A | +5,290 | +$28.25K |
| 2025-01-03 | Randall Michael Giuffre | Director | A | +10,861 | +$58.00K |
| 2025-01-03 | Richard Kuntz | Director | A | +9,925 | +$53.00K |
| 2024-07-01 | Thomas Von Koch | 10%+ Owner | Buy | +3,600,000 | +$9.00M |
| 2024-07-01 | Ab Trill | 10%+ Owner | Buy | +2,400,000 | +$6.00M |
| 2024-06-03 | Dominic R Cundari | Chief Commercial Officer | A | — | — |
| 2024-06-03 | Dietrich John Pauls | President and CEO | A | — | — |
| 2024-06-03 | Tanya Lewis | Director | A | — | — |
| 2024-06-03 | Charles Pauling Semba | Director | A | — | — |
| 2024-06-03 | Richard D. Pilnik | Director | A | — | — |
| 2024-06-03 | Scott Kellen | CFO and Secretary | A | — | — |
| 2024-06-03 | Richard Kuntz | Director | A | — | — |
| 2024-06-03 | James T. Parsons | Director | A | — | — |
| 2024-06-03 | David J. Wambeke | Chief Business Officer | A | — | — |
| 2024-06-03 | Randall Michael Giuffre | Director | A | — | — |
| 2024-01-23 | Masuoka K. Lorianne | Chief Medical Officer | A | — | — |
| 2024-01-02 | James T. Parsons | Director | A | +21,428 | +$60.00K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Ab Trill | 10%+ Owner | 8,825,742 | $77.14M |
| Thomas Von Koch | 10%+ Owner | 8,383,577 | $73.27M |
| Richard Jacinto II | 10%+ Owner | 4,958,823 | $43.34M |
| David J. Wambeke | Chief Business Officer | 527,114 | $4.61M |
| Randall Michael Giuffre | Director | 424,160 | $3.71M |
| Richard D. Pilnik | Director | 312,995 | $2.74M |
| Dietrich John Pauls | President & CEO | 128,791 | $1.13M |
| James T. Parsons | Director | 97,949 | $856.07K |
| Charles Pauling Semba | Director | 47,963 | $419.20K |
| Scott Kellen | CFO & Secretary | 32,290 | $282.21K |
| Richard Kuntz | Director | 24,210 | $211.60K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DMAC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.